quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:34:11·105d
PRRelease
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

EPRX· Eupraxia Pharmaceuticals Inc.
Health Care
Original source

Companies

  • EPRX
    Eupraxia Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 23UpdateWilliam Blair-
  • Jul 24UpdateCantor Fitzgerald$11.00
  • Jun 26UpdateH.C. Wainwright$12.00
  • Jun 16UpdateCanaccord Genuity-
  • Feb 21UpdateCraig Hallum$12.00
  • Nov 14UpdateRodman & Renshaw$9.00

Related

  • SEC2d
    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
  • PR2d
    Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
  • SEC2d
    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
  • PR3d
    Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
  • SEC9d
    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
  • SEC9d
    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
  • PR10d
    Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
  • ANALYST31d
    William Blair initiated coverage on Eupraxia Pharmaceuticals
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022